Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2011-01-11
2011-01-11
Huff, Sheela J (Department: 1643)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016700, C530S328000
Reexamination Certificate
active
07867977
ABSTRACT:
Disclosed are immunogenic peptides, related fusion proteins, nucleic acids encoding the peptides or fusion proteins, conjugates, expression vectors, host cells, and antibodies. Also, disclosed are pharmaceutical compositions, vaccines for use in the treatment or prevention of cancer, e.g., alveolar rhabodomyosarcoma, methods of stimulating a T cell to kill a tumor cell, methods of stimulating CD4+and CD8+T cells, and methods of treating or preventing cancer are further provided herein.
REFERENCES:
patent: 4450150 (1984-05-01), Sidman
patent: 5087616 (1992-02-01), Myers et al.
patent: 5225539 (1993-07-01), Winter
patent: 5449752 (1995-09-01), Fujii et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5569825 (1996-10-01), Lonberg et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5639641 (1997-06-01), Pedersen et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5714352 (1998-02-01), Jakobovits
patent: 6265150 (2001-07-01), Terstappen et al.
patent: 2002/0197266 (2002-12-01), Debinski
patent: 0 239 400 (1994-08-01), None
patent: 0 563 485 (1996-10-01), None
patent: 2 188 638 (1987-10-01), None
patent: WO 93/20185 (1993-10-01), None
patent: WO 97/10269 (1997-03-01), None
patent: WO02069900 (2002-09-01), None
Shapiro et al Cancer Research vol. 53 p. 5108 (1993).
Skolnick et al. (Trends in Biotech., 18(1):34-39, 2000).
Ahlers et al.,J. Clin. Invest., 108, 1677-1685 (2001).
Ahlers et al.,Proc. Natl. Acad. Sci USA, 94, 10856-10861 (1997).
Berzofsky et al.,J. Clin. Invest., 113 (11), 1515-1525 (2004).
Cella et al.,J. Exp. Med., 184, 747-752 (1996).
Coulie et al.,Internat. J. Can., 50, 289-297 (1992).
Dagher et al.,Med. Pediatr. Oncol., 38, 158-164 (2002).
Fredericks et al.,Molecular and Cellular Biology, 15 (3), 1522-1535 (1995).
Galili et al.,Nature Genetics, 5 (3), 230-235 (1993).
Oh et al.,Cancer Research, 64, 2610-2618 (2004).
Okazaki et al.,J. Immunol., 171, 2548-2555 (2003).
Rammensee et al.,Immunogenetics, 41 (4), 178-228 (1995).
Rodeberg et al.,Cancer Immunol. Immunotherl., 54, 526-534 (2005).
Shapiro et al.,Cancer Res., 53, 5108-5112 (1993).
Van Den Broeke,Cancer Res., 66 (3), 1818-1823 (2006).
Worley et al.,Cancer Res., 61, 6868-6875 (2001).
Berzofsky et al., “Strategies for designing and optimizing new generation vaccines,”Nat. Rev. Immunol., 1 (3), 209-219 (2001).
Choi et al., “Synthesis and assembly of a cholera toxin B subunit-rotavirus VP7 fusion protein in transgenic potato,”Mol. Biotechnol., 31 (3), 193-202 (2005).
Hudecz, “Synthesis of peptide bioconjugates,”Methods Mol. Biol., 298, 209-223 (2005).
Kirin et al., “Amino acid and peptide bioconjugates of copper(II) and zinc(II) complexes with a modified N,N-bis(2-picolyl)amine ligand,”Inorg. Chem., 44 (15), 5405-5415 (2005).
Sarobe et al., “Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions,”J. Clin. Invest., 102 (6), 1239-1248 (1998).
Smith et al., “Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing,”Int. Immunol., 9 (8), 1085-1093 (1997).
Storkus et al., “Reversal of natural killing susceptibility in target cells expressing transfected class I HLA genes,”Proc. Natl. Acad. Sci. USA, 86 (7), 2361-2364 (1999).
Berzofsky Jay A.
Helman Lee J.
MacKall Crystal
Van Den Broeke Leon T.
Huff Sheela J
Leydig , Voit & Mayer, Ltd.
The United States of America as represented by the Department of
LandOfFree
Immunogenic peptides and methods of use for treating and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunogenic peptides and methods of use for treating and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunogenic peptides and methods of use for treating and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2664797